Arcticzymes Technologies ASA - Asset Resilience Ratio

Latest as of June 2026: 20.77%

Arcticzymes Technologies ASA (AZT) has an Asset Resilience Ratio of 20.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AZT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Nkr78.75 Million
≈ $8.29 Million USD Cash + Short-term Investments

Total Assets

Nkr379.11 Million
≈ $39.89 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Arcticzymes Technologies ASA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Arcticzymes Technologies ASA total assets.

Liquid Assets Composition Over Time

This chart breaks down Arcticzymes Technologies ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read AZT current and long-term liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Nkr0.00 0%
Short-term Investments Nkr78.75 Million 20.77%
Total Liquid Assets Nkr78.75 Million 20.77%

Asset Resilience Insights

  • Good Liquidity Position: Arcticzymes Technologies ASA maintains a healthy 20.77% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Arcticzymes Technologies ASA Industry Peers by Asset Resilience Ratio

Compare Arcticzymes Technologies ASA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Biotechnology 33.23%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 65.12%

Annual Asset Resilience Ratio for Arcticzymes Technologies ASA (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Arcticzymes Technologies ASA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 73.25% Nkr264.72 Million
≈ $27.86 Million
Nkr361.41 Million
≈ $38.03 Million
+2.39pp
2024-12-31 70.86% Nkr243.94 Million
≈ $25.67 Million
Nkr344.26 Million
≈ $36.23 Million
+17.55pp
2023-12-31 53.31% Nkr180.89 Million
≈ $19.04 Million
Nkr339.32 Million
≈ $35.71 Million
-23.22pp
2022-12-31 76.53% Nkr244.16 Million
≈ $25.69 Million
Nkr319.04 Million
≈ $33.57 Million
+5.99pp
2021-12-31 70.54% Nkr200.42 Million
≈ $21.09 Million
Nkr284.11 Million
≈ $29.90 Million
+7.38pp
2020-12-31 63.17% Nkr140.18 Million
≈ $14.75 Million
Nkr221.91 Million
≈ $23.35 Million
+22.85pp
2019-12-31 40.32% Nkr31.29 Million
≈ $3.29 Million
Nkr77.61 Million
≈ $8.17 Million
-6.24pp
2018-12-31 46.55% Nkr31.66 Million
≈ $3.33 Million
Nkr68.02 Million
≈ $7.16 Million
-3.05pp
2017-12-31 49.60% Nkr30.59 Million
≈ $3.22 Million
Nkr61.68 Million
≈ $6.49 Million
-17.60pp
2016-12-31 67.19% Nkr57.67 Million
≈ $6.07 Million
Nkr85.83 Million
≈ $9.03 Million
--
pp = percentage points

About Arcticzymes Technologies ASA

OL:AZT Norway Biotechnology
Market Cap
$110.71 Million
Nkr1.05 Billion NOK
Market Cap Rank
#18891 Global
#168 in Norway
Share Price
Nkr20.60
Change (1 day)
+0.00%
52-Week Range
Nkr18.65 - Nkr30.90
All Time High
Nkr111.00
About

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids… Read more